Refractory Tumor clinical trials at UCSF
1 research study open to eligible people
A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors
open to eligible people ages 12 months to 21 years
The main purpose of this study is to evaluate the safety of the study drug known as ramucirumab in children with recurrent or refractory solid tumors including central nervous system (CNS) tumors.
San Francisco, California and other locations
Last updated: